

Pharmacokinetics, Metabolism, and in Vivo Efficacy of the Antimalarial Natural Product Bromophycolide A

Margaret E. Teasdale,[†] Jacques Prudhomme,[‡] Manuel Torres,[‡] Matthew Braley,[‡] Serena Cervantes,[‡] Shanti C. Bhatia,[†] James J. La Clair,[§] Karine Le Roch,^{*,‡} and Julia Kubanek^{*,†}

[†]School of Biology and School of Chemistry and Biochemistry, Aquatic Chemical Ecology Center and Institute of Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, Georgia 30332, United States


[‡]Department of Cell Biology and Neuroscience, University of California Riverside, Riverside, California 92521, United States

[§]Xenobe Research Institute, San Diego, California 92163, United States

S Supporting Information

ABSTRACT: A suite of pharmacokinetic and pharmacological studies show that bromophycolide A (**1**), an inhibitor of drug-sensitive and drug-resistant *Plasmodium falciparum*, displays a typical small molecule profile with low toxicity and good bioavailability. Despite susceptibility to liver metabolism and a short in vivo half-life, **1** significantly decreased parasitemia in a malaria mouse model. Combining these data with prior structure–activity relationship analyses, we demonstrate the potential for future development of **1** and its bioactive ester analogues.

KEYWORDS: Bromophycolide, malaria



The human malaria parasite, *Plasmodium falciparum*, is responsible for more than 90% of malarial infections worldwide.¹ Despite a 17% decrease in reported malarial cases and 25% reduction in malaria related deaths since 2000, there were 216 million cases of malaria reported worldwide in 2010.¹ Recently a shift in the treatment paradigm has been implemented due to rapidly increasing resistance to traditional therapies such as chloroquine, amodiaquine, mefloquine, sulfadoxine–pyrimethamine, and artemisinin.^{2,3} This paradigm shift focuses on combining an artemisinin derivative with an agent possessing a different mode of action in order to reduce the further expansion of drug resistant strains.² Unfortunately, resistance to at least one of the approved partner drugs already exists in multiple countries including Thailand and Cambodia.⁴ This fast evolution of resistance not only offers clinical challenges but has also generated an immediate need for new pharmacophores that act on resistant strains.

In 2005, the discovery of a novel class of meroditerpenes from the marine red alga *Callophycus serratus* led to their exploration as potential antimalarial leads.^{5–8} Bromophycolide A (BrA; **1**; Figure 1), the most abundant member of this compound class, exhibited submicromolar inhibition of both chloroquine-sensitive and chloroquine-resistant *P. falciparum*.⁹ Mechanistic studies revealed that **1** prevents heme detoxification, a vital process for the parasite during its bloodborne stages.⁹ Drugs such as chloroquine that target heme detoxification have had great success in malaria treatment, despite emergence of drug resistance.¹⁰ Although both chloroquine and **1** prevent heme detoxification in the parasite, **1** is unaffected by the resistance mechanism *P. falciparum* has




Figure 1. Structures of bromophycolide A (**1**) and its semisynthetic derivative 18-acetyl-BrA (**2**).

evolved for chloroquine, providing support for its further development.⁹

Lead optimization requires identification of biochemical and physicochemical properties such as clearance from the bloodstream, distribution between blood and other tissues, and understanding of metabolic fate in order to focus drug modification efforts. Here we report on these parameters, including in vivo efficacy, which ascertain key properties of **1** toward deriving a clinical drug candidate.

In mice infected with *Plasmodium yoelii* dosed once daily with **1** at 10 mg/kg, after four days the parasite load was $47 \pm 12\%$ lower than in infected mice injected with vehicle only (Figure 2). Fluorescence activated cell sorter (FACS) data revealed a final parasitemia of $32 \pm 2\%$ for control animals compared to $17 \pm 4\%$ for those dosed at 10 mg/kg and $20 \pm 1\%$ dosed at 5 mg/kg. Twenty-four hours after the first dose of 10 mg/kg, parasitemia was 27% lower for treated than control mice. After

Received: July 19, 2013

Accepted: September 2, 2013

Published: September 2, 2013




Figure 2. Bromophycolide A (**1**) decreases parasitemia in vivo. BrA (**1**) was administered to Swiss webster female mice on day 2 after confirmation of infection with *Plasmodium yoelii*. Experiment was terminated on day 5 and daily parasite load determined by FACS analysis by staining the parasites with Hoechst 33342 ($n = 3$; \pm standard deviation [SD]).

the second dose, parasite load was 55% lower, reflected in $10.0 \pm 0.5\%$ vs $4.5 \pm 1.5\%$ parasitemia in treated vs control mice, respectively. BrA (**1**) was nontoxic to mice with this dosing regime. At the termination of efficacy trials, the concentration of **1** in blood and plasma of infected mice was below the limit of detection, indicating rapid elimination of **1** from the blood.

BrA (**1**) has previously been shown to potently inhibit the malaria parasite *P. falciparum* in vitro, having an IC_{50} of 499 nM against chloroquine-sensitive parasites and an IC_{50} of 377 nM against chloroquine-resistant parasites.⁹ In comparison to the few reported in vivo efficacies of other nonartemisinin derived antimalarial natural products, the activity of **1** is promising but not exceptional. For instance, gomphostenin A, which displayed an in vitro IC_{50} of 8.8 μ M against *P. falciparum*, only suppressed parasitemia in vivo by 45% when dosed orally at 50 mg/kg,¹¹ which is less efficacious than **1**. Other leads displayed improved in vivo activity. For instance, spiro-tetrahydro- β -carboline NITD609, which displayed in vitro IC_{50} value of 0.9 nM against *P. falciparum*, was significantly more active in vivo than **1**, reducing mouse parasitemia by 99% when dosed orally at 10 mg/kg.¹² Similarly, simalikalactone E, with an in vitro IC_{50} of 24–68 nM, reduced parasitemia in vivo by 50% at 0.5 mg/kg IP dosing and 1 mg/kg oral dosing.¹³

The encouraging decrease in mouse parasitemia associated with BrA treatment (Figure 2) was observed despite the rapid elimination of **1** from systemic circulation. The pharmacokinetic profile of **1**, determined following single injections by intravenous (IV) or intraperitoneal (IP) dosing to healthy mice, is characterized by rapid, but short-lived, pharmacological effects in vivo, as shown by a first order elimination process, short half-life, high clearance, fast absorption, and good bioavailability (Table 1; Figure 3). The preliminary pharmacokinetics displayed a high plasma clearance (Cl) of 16 ± 3 mL/min/kg in mice following IV administration. This is similar to the clearance rate for chloroquine (17 mL/min/kg),¹⁴ but higher than the spiroindolone NITD609, whose clearance rate in mice was shown to be 9.8 mL/min/kg.^{12,15}

BrA (**1**) has a short in vivo residence as displayed by an IV half-life of 0.75 ± 0.11 h. However, this value is not limiting as the marketed antimalarial drug, artesunate, exhibits a half-life of less than 10 min by IV dosing.¹⁶ Additionally, a short plasma half-life suggests a decreased probability of the evolution of drug-resistance in the parasite.¹⁷ The apparent volume of distribution, 0.95 ± 0.27 L/kg of body weight, following IV

Table 1. Pharmacokinetic Parameters Following Either Intravenous Bolus (IV) or Intraperitoneal (IP) Injection of BrA (**1**) in Mice ($n = 3$; mean \pm SD)

parameter	units	IV	IP
dose	mg/kg	23	23
K_{el}	h^{-1}	0.93 ± 0.13	
K_{ab}	h^{-1}		0.24 ± 0.03
$t_{1/2}$	h	0.75 ± 0.11	
C_{max}	μ g/mL		5.8 ± 3.9
T_{max}	h		1.5
AUC	μ g·h/mL	26 ± 5	20
C_p^0	μ g/mL	24 ± 6	
V_d	L/kg	0.95 ± 0.27	
CL	mL/min/kg	16 ± 3	




Figure 3. In vivo pharmacokinetic study of BrA (**1**) by a single intravenous (IV) or intraperitoneal (IP) injection. Data points are mean plasma concentration ($n = 3$, \pm SD). Initial dose was 23 mg/kg.

dosing, is greater than the body of water volume suggesting that **1** is moderately distributed to the tissues, with a portion remaining in systemic circulation to be transferred throughout the body. In contrast, chloroquine has a much larger apparent volume of distribution of 200 L/kg, indicating primary localization in nonblood tissues, with very little of the drug remaining in the plasma circulating throughout the body.¹⁴

The rapid removal of **1** from systemic circulation as indicated by the preliminary pharmacokinetic study would suggest a much lower in vivo efficacy than achieved by **1** in the mouse model (Figure 2). Therefore, in the context of pharmacokinetic modeling, the in vivo efficacy of **1** is better than expected.

Despite its rapid clearance rate and low half-life, **1** did not suffer decomposition or loss of solubility in serum. Blood contains many enzymes that can lead to rapid degradation and erroneous pharmacokinetic parameters.¹⁸ While no significant loss of **1** was observed after incubation in mouse serum at 37 °C for 24 h ($r^2 = 0.20$, $p = 0.27$), a $27 \pm 9\%$ loss was observed after 48 h. These data indicate that **1** is stable in mouse serum over 24 h and is not subject to rapid degradation by blood enzymes.

In contrast to its stability in serum, we found that human liver enzymes efficiently metabolized **1**. In order to establish the most active routes to BrA metabolism in a model relevant for drug development, we used human liver enzymes to model the metabolic profile of BrA. As negligible metabolism of BrA was observed after 4 h, experiments with the human liver subcellular fractions were extended to 24 h. Incubation in the presence of the S9 liver fraction significantly decreased the concentration of **1** in the reaction mixture by $55 \pm 4\%$ over 24 h (Figure 4); no such metabolism was noted in the absence of enzyme or




Figure 4. BrA (**1**) is metabolized by human liver subcellular fractions in vitro ($n = 3$; \pm SD).

NADPH (data not shown). Calculated apparent intrinsic clearance (CL_{int}) for **1** exposed to the S9 fraction was 0.52 ± 0.06 mL/min/kg with an in vitro $t_{1/2}$ of 20 ± 2 h. Upon the addition of the glucuronidation cofactor UDPGA, **1** was subject to an additional 21% metabolism when exposed to the S9 liver fraction (Figure 5). The calculated CL_{int} for **1** exposed to the




Figure 5. Glucuronidation is a significant pathway for the metabolism of BrA (**1**), as exhibited by the addition of UDPGA ($n = 3$; \pm SD).


S9 fraction with UDPGA was 1.1 ± 0.1 mL/min/kg with an in vitro $t_{1/2}$ of 9.5 ± 0.8 h, almost double the CL_{int} without UDPGA, indicating that glucuronidation is a major pathway in the metabolism of **1**.

In order to identify the liver enzymes and products involved in its metabolism, we exposed **1** to both microsomal and cytosolic subcellular fractions in addition to the S9 liver enzymes, resulting in dramatically different profiles ($p \leq 0.020$ comparing all three treatments at $t = 6$ and 24 h). Incubation of **1** with the microsomal subcellular fraction resulted in a comparable result as that obtained with exposure to S9 enzymes (Figures 4 and 5). Without the addition of UDPGA, the concentration of **1** was reduced by $61 \pm 1\%$ in the presence of human liver microsomes. The calculated CL_{int} of the microsomal fraction was 0.72 ± 0.09 mL/mg/kg with a $t_{1/2}$ of 14 ± 4 h. In the presence of UDPGA, only $15.3 \pm 3\%$ of **1** remained after 24 h with a calculated CL_{int} of 1.6 ± 0.5 mL/min/kg with a $t_{1/2}$ of 6.6 ± 1.9 h. The same distinction seen with the S9 subcellular fraction between incubations with UDPGA and without is noted, further supporting the role of glucuronidation as a major pathway in the metabolism of **1**. However, **1** was stable in the presence of the human liver cytosolic fraction ($r^2 = 0.24$, $p = 0.10$; Figure 3).

LC–MS analysis of the reaction products of **1** treated with S9 or microsomal enzymes supported the production of

hydroxylated (m/z 677) and doubly hydroxylated (m/z of 693) metabolites such as M1–M4 (Scheme 1) in the absence of

Scheme 1. Possible Phase I and II Liver Metabolites of BrA(**1**) Based on LC–MS Analysis; Shaded Regions Denote the Position of Modification



UDPGA. Both microsomal and cytosolic fractions contain methyl transferases, glutathione-S-transferases, and reductases.¹⁹ Unique to the microsomal fraction are cytochrome P450 enzymes and UDP-glucuronosyltransferases.¹⁹ Detection of hydroxylated derivatives of bromophycolide A with the S9 and microsomal fraction in the presence of NADPH suggested that cytochrome P450 monooxygenases are involved in liver metabolism of **1**. In the presence of UDPGA, a glucuronidated metabolite, potentially M5, was detected (m/z 837) (Scheme 1), providing evidence for the role of UDP-glucuronosyltransferases in the metabolism of **1**.

The macrocyclic lactone of **1** was surprisingly tolerant to both blood and liver, which contain a diversity of hydrolytic enzymes that can rapidly hydrolyze esters, lactones, amides, and lactams.¹⁸ The fact that products of hydrolysis of the macrolactone core of **1** were not detected in either the liver metabolism or mouse serum experiments provides strong support that the core motif of **1** is a stable entity.

Phase I hydroxylation of **1** may occur on either the aromatic ring or on the aliphatic methyl group (Scheme 1), although we were unsuccessful at definitively placing these functional groups by MS/MS analysis or via isolation and NMR characterization of metabolic products. Successful modifications to prevent hydroxylation at metabolically reactive sites on the aromatic ring have been performed by halogenation of the spiroindolone

NITD609. Incorporation of either a fluorine or chlorine in both the positions meta and para to the pyrrole significantly increased the metabolic half-life and in vivo efficacy of spiroindolone NITD609.²⁰ Comparable methods have also been seen for other leads such as triazolopyrimidine where replacement of an aromatic hydrogen with a trifluoromethyl group dramatically enhanced metabolic stability and in vivo efficacy.²¹

Hydroxyl groups make **1** susceptible to glucuronidation, which is expected to primarily occur at the aromatic hydroxyl group.²² The phenol of **1** has been previously shown to be vital to biological activity as the methylation of this functional group led to complete loss of in vitro activity.⁹ Thus, protecting the phenol could stabilize **1** in the presence of liver enzymes. The addition of electron withdrawing halogens to the aromatic ring could result in a reduction in the glucuronidation of the phenol of **1**.²³ Alternatively, esterification of the phenol may also reduce phase II glucuronidation, creating a pro-drug motif cleaved in the presence of hydrolytic enzymes found in the blood, releasing **1**.²⁴ This route is promising as semisynthetic 18-acetyl-BrA (**2**) exhibits an IC₅₀ value of 241 nM in vitro against *P. falciparum*.⁹

BrA (**1**) exhibits poor solubility in aqueous buffers (c log P = 8.8) relative to desirable drug candidates with c log P under 5.²⁵ To date, we have been able to solubilize **1** starting from a solution in DMSO using serial dilutions with solutol HS-15 in saline solution. Attempts using other common materials such as Tween-80, cyclodextrins, and polyethylene glycol 400 failed. Expansion of next generation ester analogues could include the incorporation of alkoxy amines^{26,27} or the addition of a phosphate group as a further modified prodrug-motif.²⁸

Overall, in comparison to current early lead criteria published by the Medicines for Malaria Venture (MMV),²⁹ **1** represents a relatively strong candidate for further development. BrA (**1**) has an in vitro potency against both drug-sensitive and drug-resistant parasites less than the required 1 μM with an established mode of action. BrA (**1**) is stable in mouse serum and moderately stable in the presence of human microsomes. The lack of mouse toxicity (in either the PK study or the in vivo efficacy study) and significant reduction in parasitemia in vivo despite a short half-life suggests promise. Previously published data indicate that **1** displays 10-fold differential selectivity among eukaryotic cell lines, having an IC₅₀ above 6 μM against human cancer cells.⁵ Although **1** is not “rule-of-5” compliant and is poorly soluble in buffer, this study identifies key metabolic issues and provides a first step toward developing a strong structure pharmacologic relationship (SPR) map for indicating the next step to deliver a viable clinical lead.

■ ASSOCIATED CONTENT

📄 Supporting Information

Detailed materials, methods, and procedures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Authors

*Phone: +1 951-827-5422. E-mail: karine.leroch@ucr.edu.

*Phone: +1 404-894-8424. E-mail: julia.kubanek@biology.gatech.edu.

Funding

This work was supported by ICBG grant U01-TW007401 from the Fogarty International Center of the U.S. National Institutes of Health and National Science Foundation.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the Government of Fiji and the customary fishing right owners for permission to perform research in their territorial waters. We also thank M. Hay and C. Clements for collection of algal samples, E. Platzer for providing the *P. yoelii* strain, and B. Walter for performing FACS analysis.

■ ABBREVIATIONS

BrA, bromophycolide A; DMSO, dimethylsulfoxide; MeOH, methanol; CH₃CN, acetonitrile; UDPGA, uridine 5'-diphosphoglucuronic acid trisodium salt; FACS, fluorescence-activated cell sorting; IV, intravenous; IP, intraperitoneal; K_{el}, first order rate constant for the elimination phase; K_{ab}, first order rate constant for the absorption phase

■ REFERENCES

- (1) WHO. *World Malaria Report*; WHO: Geneva, Switzerland, 2011; pp 1–121.
- (2) WHO. *Global Report on Antimalarial Drug Efficacy and Drug Resistance 2000–2010*; WHO: Geneva, Switzerland, 2010.
- (3) Dondorp, A. M.; Yeung, S.; White, L.; Nguon, C.; Day, N. P. J.; Socheat, D.; von Seidlein, L. Artemisinin resistance: current status and scenarios for containment. *Nat. Rev. Microbiol.* **2010**, *8*, 272–275.
- (4) Wongsrichanalai, C.; Sirichaisinthop, J.; Karwacki, J. J.; Congpuong, K.; Miller, R. S.; Pang, L.; Thimasarn, K. Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian borders. *Southeast Asian J. Trop. Med. Public Health* **2001**, *32*, 41–49.
- (5) Kubanek, J.; Prusak, A. C.; Snell, T. W.; Giese, R. A.; Hardcastle, K. I.; Fairchild, C. R.; Aalbersberg, W.; Raventos-Suarez, C.; Hay, M. E. Antineoplastic diterpene-benzoate macrolides from the Fijian red alga *Callophycus serratus*. *Org. Lett.* **2005**, *7*, 5261–5264.
- (6) Kubanek, J.; Prusak, A. C.; Snell, T. W.; Giese, R. A.; Fairchild, C. R.; Aalbersberg, W.; Hay, M. E. Bromophycolides C-I from the Fijian red alga *Callophycus serratus*. *J. Nat. Prod.* **2006**, *69*, 731–735.
- (7) Lane, A. L.; Stout, E. P.; Lin, A. S.; Prudhomme, J.; Le Roch, K.; Fairchild, C. R.; Franzblau, S. G.; Hay, M. E.; Aalbersberg, W.; Kubanek, J. Antimalarial bromophycolides J-Q from the Fijian red alga *Callophycus serratus*. *J. Org. Chem.* **2009**, *74*, 2736–2742.
- (8) Lin, A. S.; Stout, E. P.; Prudhomme, J.; Le Roch, K.; Fairchild, C. R.; Franzblau, S. G.; Aalbersberg, W.; Hay, M. E.; Kubanek, J. Bioactive bromophycolides R-U from the Fijian red alga *Callophycus serratus*. *J. Nat. Prod.* **2010**, *73*, 275–278.
- (9) Stout, E. P.; Cervantes, S.; Prudhomme, J.; France, S.; La Clair, J. J.; Le Roch, K.; Kubanek, J. Bromophycolide A targets heme crystallization in the human malaria parasite *Plasmodium falciparum*. *ChemMedChem* **2011**, *6*, 1572–1577.
- (10) Na-Bangchang, K.; Karbwang, J. Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development. *Fundam. Clin. Pharmacol.* **2009**, *23*, 387–409.
- (11) Sathe, M.; Kaushik, M. P. Gomphostenins: two new antimalarial compounds from the leaves of *Gomphostemma niveum*. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 1312–1314.
- (12) Rottmann, M.; McNamara, C.; Yeung, B. K. S.; Lee, M. C. S.; Zou, B.; Russell, B.; Seitz, P.; Plouffe, D. M.; Dharia, N. V.; Tan, J.; Cohen, S. B.; Spencer, K. R.; Gonzalez-Paez, G. E.; Lakshminarayana, S. B.; Goh, A.; Suwanarusk, R.; Jegla, T.; Schmitt, E. K.; Beck, H. P.; Brun, R.; Nosten, F.; Renia, L.; Dartois, V.; Keller, T. H.; Fidock, D.

A.; Winzeler, E. A.; Diagona, T. T. Spiroindolones, a potent compound class for the treatment of malaria. *Science* **2010**, *329*, 1175–1180.

(13) Cachet, N.; Hoakwie, F.; Bertani, S.; Bourdy, G.; Deharo, E.; Stien, D.; Houel, E.; Gornitzka, H.; Fillaux, J.; Chevalley, S.; Valentin, A.; Jullian, V. Antimalarial activity of simalikalactone E, a new quassinoid from *Quassia amara* L. (Simaroubaceae). *Antimicrob. Agents Chemother.* **2009**, *53*, 4393–4398.

(14) Moore, B. R.; Page-Sharp, M.; Stoney, J. R.; Ilett, K. F.; Jago, J. D.; Batty, K. T. Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. *Antimicrob. Agents Chemother.* **2011**, *55*, 3899–3907.

(15) Friskholmlberg, M.; Bergqvist, Y.; Termond, E.; Domeijnyberg, B. The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy-subjects. *Eur. J. Clin. Pharmacol.* **1984**, *26*, 521–530.

(16) Morris, C. A.; Duparc, S.; Borghini-Fuhrer, I.; Jung, D.; Shin, C. S.; Fleckenstein, L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. *Malar. J.* **2011**, *10*, 263–280.

(17) MMV. *Development of Combination Therapies for the Treatment of Uncomplicated Plasmodium falciparum Malaria*; MMV: Geneva, Switzerland, 2010.

(18) Di, L.; Kerns, E. H. Solution stability: plasma, gastrointestinal, bioassay. *Curr. Drug Metab.* **2008**, *9*, 860–868.

(19) Kerns, E.; Di, L. *Drug-Like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization*; Academic Press: New York, 2008.

(20) Chatterjee, A. K.; Yeung, B. K. Back to the future: lessons learned in modern target-based and whole-cell lead optimization of antimalarials. *Curr. Top. Med. Chem.* **2012**, *12*, 473–483.

(21) Coteron, J. M.; Marco, M.; Esquivias, J.; Deng, X. Y.; White, K. L.; White, J.; Koltun, M.; El Mazouni, F.; Kokkonda, S.; Katneni, K.; Bhamidipati, R.; Shackelford, D. M.; Angulo-Barturen, I.; Ferrer, S. B.; Jimenez-Diaz, M. B.; Gamo, F. J.; Goldsmith, E. J.; Charman, W. N.; Bathurst, I.; Floyd, D.; Matthews, D.; Burrows, J. N.; Rathod, P. K.; Charman, S. A.; Phillips, M. A. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent *Plasmodium falciparum* dihydroorotate dehydrogenase inhibitors with clinical candidate potential. *J. Med. Chem.* **2011**, *54*, 5540–5561.

(22) Wu, B. J.; Basu, S.; Meng, S. N.; Wang, X. Q.; Hu, M. Regioselective sulfation and glucuronidation of phenolics: insights into the structural basis. *Curr. Drug Metab.* **2011**, *12*, 900–916.

(23) Madsen, P.; Ling, A.; Plewe, M.; Sams, C. K.; Knudsen, L. B.; Sidelmann, U. G.; Ynddal, L.; Brand, C. L.; Andersen, B.; Murphy, D.; Teng, M.; Truesdale, L.; Kiel, D.; May, J.; Kuki, A.; Shi, S. H.; Johnson, M. D.; Teston, K. A.; Feng, J.; Lakis, J.; Anderes, K.; Gregor, V.; Lau, J. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid[1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. *J. Med. Chem.* **2002**, *45*, 5755–5775.

(24) Hussain, M. A.; Shefter, E. Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs. *Pharm. Res.* **1988**, *5*, 113–115.

(25) Hill, A. P.; Young, R. J. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. *Drug Discovery Today* **2010**, *15*, 648–655.

(26) Arrowsmith, J. E.; Campbell, S. F.; Cross, P. E.; Stubbs, J. K.; Burges, R. A.; Gardiner, D. G.; Blackburn, K. J. Long-acting dihydropyridine calcium-antagonists. 1.2-Alkoxyethyl derivatives incorporating basic substituents. *J. Med. Chem.* **1986**, *29*, 1696–1702.

(27) Lundquist, J. T.; Harnish, D. C.; Kim, C. Y.; Mehlmann, J. F.; Unwalla, R. J.; Phipps, K. M.; Crawley, M. L.; Commons, T.; Green, D. M.; Xu, W. X.; Hum, W. T.; Eta, J. E.; Feingold, I.; Patel, V.; Evans, M. J.; Lai, K.; Borges-Marcucci, L.; Mahaney, P. E.; Wrobel, J. E. Improvement of physicochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. *J. Med. Chem.* **2010**, *53*, 1774–1787.

(28) Stella, V. J.; Nti-Addae, K. W. Prodrug strategies to overcome poor water solubility. *Adv. Drug Delivery Rev.* **2007**, *59*, 677–694.

(29) MMV. *MMV Compound Progression Criteria—August 2008*; MMV: Geneva, Switzerland, 2008.